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ABSTRACT 
 
Introduction 
Patients are unwilling to participate in clinical trials if they perceive risks. To identify how 
trial participation impacts on outcome, outcomes were evaluated following surgery for gastro-
oesophageal reflux in patients recruited to randomised trials vs. patients not in trials. 
 
Patients and Methods 
From 1994 to 2009, 417 patients entered 6 randomised trials evaluating surgery for reflux, 
and 980 underwent surgery outside the trials. The choice of procedure outside the trials was 
according to surgeon or patient preference. Clinical outcomes were determined 1 and 5 years 
after surgery using a standardised questionnaire, including analogue scales to assess heartburn 
and dysphagia, and overall satisfaction with the outcome. Subgroup analysis was undertaken 
for those aged < 75 yrs undergoing laparoscopic Nissen fundoplication. 
 
Results 
The trial group contained a higher proportion of men, were younger, more likely to have 
Barrett’s oesophagus, and have undergone a Nissen fundoplication. Reoperations within 5 
years were more common in the trials group. At one year patients in the trials had slightly 
lower heartburn scores, and less abdominal bloating, but otherwise similar outcomes to those 
not in the trials. At five years there were no differences except a slightly higher dysphagia 
score for liquids in the trials group. For the subgroup analysis demographic data were similar 
for both groups, and at one year there were no differences. At 5 yrs patients enrolled in the 
trials had higher scores for dysphagia for liquids. The magnitude of all statistically significant 
differences were unlikely to be clinically significant. 
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Conclusion 
Participation in a randomised trial assessing surgery for reflux does not impact outcomes. 
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INTRODUCTION 
 
Whilst randomised controlled trials are often undertaken, and the data obtained from such 
studies underpins the evidence base for current clinical practice, not all patients who meet 
inclusion criteria for such trials are willing to participate. There might be significant barriers 
which prevent enrolment in clinical trials, one being the perception held by some individuals 
that participation makes them a “guinea pig”, and consequently participating might lead to 
harm. Whilst there could be some truth in this perception, particularly for early phase 
pharmaceutical trials, an alternative view is sometimes proposed that patients enrolled in 
clinical trials have better outcomes, irrespective of whether they are in a treatment or control 
arm, and this might be due more intensive treatment or more careful follow-up
1
. If this is 
correct, participation in a clinical trial might actually be beneficial. Hence, it is important to 
know whether participation in a randomised clinical trial is advantageous to participants, or 
whether it is detrimental, and the answer to this question should influence whether clinicians 
encourage or discourage their patients to participate in trials.  
 
The answer to this question will be influenced by the context of specific trials. This has been 
addressed to some extent within the setting of clinical trials of cytotoxic agents used for the 
treatment of cancer
1
. Several systematic reviews have addressed this question by pooling data 
from published trials
1,2,3
, but these reviews have not demonstrated any outcome differences 
between patients in trials vs. outside trials. These analyses might be criticised, however, for 
not analysing raw data sets which have been structured to specifically address this question. 
Further, there are no published studies, which have addressed this issue by comparing patients 
from a single centre, or studies which have evaluated the question within the context of a 
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surgical treatment.  
 
Since 1994, we have conducted a series of randomised controlled trials to evaluate variations 
in surgical procedures for the treatment of gastro-oesophageal reflux
4,5,6,7,8
, and concurrently 
we have prospectively followed all patients undergoing surgery for reflux using a similar 
clinical protocol, irrespective of whether or not they were enrolled in one of the trials
9
. This 
now provides an opportunity to determine whether enrolment in a randomised trial impacts on 
outcome following antireflux surgery. We have done this by comparing the outcome for 
patients who were entered into a randomised trial with those individuals who concurrently 
underwent similar surgery outside of these trials. 
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PATIENTS AND METHODS 
 
From April 1994 to December 2009, patients with gastro-oesophageal reflux who presented 
for primary laparoscopic antireflux surgery were considered for inclusion in a series of 
randomised controlled trials evaluating different surgical techniques for the treatment of 
reflux. These trials entailed: 
 Nissen fundoplication with vs. without division of short gastric vessels4 
 Nissen vs. anterior 1800 partial fundoplication5 
 Nissen fundoplication with anterior vs. posterior hiatal repair6 
 Nissen vs. anterior 900 partial fundoplication7,8 
 Anterior 1800 vs. posterior partial fundoplication 
The full details of these trials and the procedures employed have been reported 
previously
4,5,6,7,8
. At the same time identical surgical techniques were used for patients 
undergoing surgery for reflux outside of these trials. These techniques entailed either a Nissen 
(360°) or partial (anterior 90°, anterior 180°, or posterior) fundoplication, and the choice of 
procedure outside the trials was according to surgeon or patient preference.  
 
Following surgery patients enrolled in the trials, as well as those not enrolled, all underwent 
follow-up using the same standardized clinical questionnaire
4
. The questionnaire was 
administered by a research nurse at 3 and 12 months following surgery, and then annually 
thereafter. Information was collected prospectively, and managed on a computerised database 
(FileMaker Pro, Version 11.0). The presence or absence of heartburn, and dysphagia for 
liquids and solids, was graded using previously reported 0 to 10 analog scales (0 = no 
symptoms; 10 = severe symptoms). Patient satisfaction was also measured using an analog 
scale (0 = unsatisfied, 10 = highly satisfied). The presence or absence of abdominal bloating 
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was also determined using a yes/no question. For the current study, we analysed outcome data 
collected at 1 and 5 years follow-up time points to standardise the assessment of outcome.  
 
Patients were excluded from the current study if they underwent surgery before the first 
randomised trial commenced (April 1994), or if they met exclusion criteria for the randomised 
trials; i.e. a large hiatus hernia containing more than 50% of the stomach, or the first operation 
in our Department was a revision procedure. Patients were divided into two groups according 
to whether or not they were enrolled in a trial: a “trial” group which included all patients 
entered into a randomised controlled trial, and a “non-trial” group which encompassed all 
other patients undergoing primary surgery for reflux. The clinical outcomes for the trial vs. 
non-trial groups were then compared. 
 
To further minimise potential selection and outcome differences between the 2 study groups 
we undertook a subgroup analysis, in which we excluded all patients who had not undergone 
a Nissen fundoplication, and all patients over 75 years of age (n=2). Within this cohort, the 
trial vs. non-trial groups were again compared. 
 
Statistical analysis was undertaken using SAS version 9.2  for Microsoft Windows XP 
Professional,  and Instat version 3.1 (GraphPad Software Inc) software. Categorical variables 
are presented as n (%). Continuous variables are presented as Mean (standard deviation (SD). 
For comparison between groups Fischer´s Exact test was used for dichotomous variables and 
the Chi Square test was used for non-ordered categorical variables. Matel-Haenszel Chi 
Square test was used for ordered categorical variables and the Mann-Whitney U-test was used 
for continuous variables. The clinical trials and follow-up undertaken in this study were 
approved by the Human Clinical Research Ethics Committees at the Royal Adelaide Hospital 
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and Flinders Medical Centre, in Adelaide, South Australia. 
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RESULTS 
 
From April 1994 to February 2009, 1397 patients underwent laparoscopic surgery for gastro-
oesophageal reflux and met the entry criteria for this study. 417 were enrolled in a prospective 
randomised trial (trial group), and 981 concurrently underwent surgery outside the trials (non-
trial group). Demographic details are summarised in Table 1. The trial group contained a 
higher proportion of men, were on average 2.5 years younger, were less likely to have 
Barrett’s oesophagus, and were more likely to have undergone a Nissen fundoplication.  
 
Follow-up is summarised in Figure 1 and Table 2. During the first year of follow up, 2 
patients in the trial group died and 38 (9.1%) did not provide clinical follow-up data at the 1 
year time point, whereas in the non-trial group 4 patients died in the first year, and 194 
(19.8%) did not provide follow-up data at the 1 year time point. No deaths were related to the 
antireflux surgery procedures. Clinical outcome data was available for 377 (90.8%) patients in 
the trial group vs. 782 (80.2%) in the non-trial group at the 1 year follow-up point. At 1 year, 
no differences were seen in the analog scores for dysphagia or satisfaction, although the score 
for heartburn was significantly lower, and more patients reported symptoms of abdominal 
bloating in the non-trial group (56.7% vs. 50.3% p=0.0462). 
 
389 patients in the trial group and 714 in the non-trial group (total = 1003) underwent surgery 
5 or more years before the data analysis was conducted. At 5 years follow-up, 4 more patients 
in the trial group had died, and 11 (2.8%) of the trial group provided no follow up data. 
Hence, an outcome was available from 378 (97.2%) patients at 5 years. In the non-trial group 
18 further patients had died by 5 yrs, and outcome data was not available for 45 (6.3%) of the 
non-trial group. Hence, an outcome was available for 669 (93.7%) (Figure 1). At five years 
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symptom scores were similar for both groups, except for dysphagia for liquids which was 
higher in the trial group (Table 2). Both groups reported similar satisfaction scores at five 
years follow up. There were no differences in bloating symptoms for the 2 groups, with 
49.2% of the trial group and 51.8% (P=0.524) of the non-trial group reporting this symptom 
at 5 years.  
 
Reoperative antireflux surgery within the first 5 years of follow-up was similar for the 2 
groups, with 37 (8.9%) of the trial group and 67 (6.8%) of the non-trial undergoing revisional 
surgery (P=0.183). Within the trial group, 7 underwent revision for recurrent reflux, 23 for 
dysphagia, 5 for post-operative hiatus hernia and 2 for other reasons (postoperative bleeding - 
1, bloating symptoms - 1), compared to 20, 33, 9 and 5 (bloating – 2, non-specific pain -1, 
oesophageal perforation -2) respectively in the non-trial group. 
 
The results of the subgroup analysis in the patients aged less than 75 years who underwent a 
Nissen fundoplication are summarised in Tables 3 and 4, and Figure 2. The trial vs. non-trial 
groups within this subgroup were well matched for gender, age, BMI and presence of 
Barrett’s oesophagus. Completeness of follow-up at 1 and 5 years for the subgroups is 
summarised in Figure 2. In the first year of follow-up one patient from each group died. An 
outcome was available at 1 year from 302 (90.4%) of patients in the trial group and 429 
(78.3%) in the non-trial group. There were no significant differences between the 2 groups for 
the heartburn, dysphagia and satisfaction scores. 62% patients in the trial group and 68% of 
the non-trial group reported bloating symptoms at 1 year (p=0.151). 
 
At 5 years follow-up, 3 further patients died in the trial subgroup, and 5 in the non-trial 
subgroup. Clinical follow-up at 5 years was available for 324 (97.0%) patients from the trial 
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group and 407 (93.1%) from the non-trial group for the subgroup analysis. At 5 years the 
mean analog scores for heartburn and dysphagia for liquids were slightly higher in the trial 
group. Scores for dysphagia for solids and satisfaction were similar for the 2 groups. The 
number of patients reporting bloating symptoms at 5 years was also similar; 65% in the trial 
group vs. 64% in the non-trial group (p=0.846). 
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DISCUSSION 
 
In our departments we have conducted a series of randomised controlled trials which evaluate 
outcomes following antireflux surgery, and we have applied similar standardised 
questionnaires to the prospective assessment of reflux symptoms and other postoperative 
outcomes in all of the patients enrolled in these trials, and have concurrently used the same 
questionnaire for prospective follow-up of patients who concurrently underwent surgery 
outside of these trials
4,5,6,7,8,9
. This has provided a unique opportunity to evaluate the impact of 
trial participation on clinical outcomes for a surgical procedure, laparoscopic fundoplication.  
 
Our results demonstrated that the trial vs. non-trial groups were similar preoperatively for 
most parameters, except sex, age, and the balance of fundoplication types performed. A larger 
proportion of patients underwent a Nissen rather than a partial fundoplication within the 
clinical trials, probably due to standardisation to a Nissen fundoplication in 2 of the first 3 
trials conducted
4,6
, as well as a tendency to construct a partial fundoplication more often 
outside the trials once we were satisfied with the longer term outcomes for anterior 180
0
 
partial fundoplication
10
. Standardisation of the selection criteria and operation type for the 
non-trial vs. trial groups, removed all of the preoperative differences, providing well 
standardised groups. 
 
At one year follow-up the only statistically significant difference in symptoms was a slightly 
higher mean heartburn score in the group not enrolled in the trials. At 5 years follow up the 
only statistically significant difference was a slightly higher mean dysphagia score for liquids 
in the group enrolled in the trials. However, neither of these differences are likely to reflect 
clinically important differences, as the magnitudes of the actual differences were quite small. 
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In the matched subgroup analysis, the only statistically significant differences were slightly 
higher heartburn and liquid dysphagia scores at 5 years in the trial group, but again the 
magnitudes of the differences were very small, and unlikely to be clinically important. 
Overall, our results suggest equivalent outcomes for patients enrolled in randomised trials vs. 
those not enrolled, and no disadvantages associated with participation in this type of 
randomised controlled trial. This should provide reassurance to patients that they can safely 
enter a randomised trial, at least in the context of antireflux surgery. Further, as our results 
demonstrate equivalence of outcomes for patients inside and outside the randomised trials, 
this also suggests that the results from the randomised trials should be generalisable to the 
whole population of people undergoing surgery for gastro-oesophageal reflux. 
 
In the past, it has been suggested that participants in trials might actually have an improved 
outcome, compared to their counterparts who do not participate
1
, and this has been used an 
argument to support trial enrolment. There are various reasons why this might occur, and 
these include a treatment effect by which the participant benefits from an improved treatment; 
as well as a participation effect or “trial effect” which can be subdivided in four sub-effects. 
These include a protocol effect due to improved processes and outcomes, a care effect due to 
extra follow up and extra nursing care, a “Hawthorne effect” due to changes in patient and 
clinician behaviour, and a placebo effect due to changes in effects due to informed consent
2
. 
Other differences between individuals who participate vs. do not participate in trials include 
confounding factors such as sex, age, ethnic origin, and socioeconomic status. In addition, 
bias can be introduced, depending on how data is collected and the completeness of follow 
up. Finally, publication bias can occur due to failure to publish studies reporting negative trial 
effects. Other literature which has compared outcomes between patients enrolled in clinical 
trials vs. outside trials derives mainly from the field of oncology, and this has failed to show 
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better outcomes for patient enrolled in randomised trials compared with those receiving the 
same or similar treatment outside such trials
1,2,3
. Our study is the first to evaluate the impact 
of trial participation on outcome following a surgical procedure, and our data support the 
conclusion that participation in a randomised clinical trial, at least in the context of antireflux 
surgery, did not adversely impact the clinical outcome.  
 
There are, however, some limitations to our study. We have only looked at patients 
undergoing surgery for gastro-oesophageal reflux, and the results might be different for other 
patient cohorts undergoing different procedures, although we can find no evidence to support 
any negative benefit associated with enrolment in a randomised trial of any sort. Our outcome 
measures were standardised clinical scores, and for the current study we did not evaluate the 
outcome of antireflux surgery using any objective investigations. Nevertheless, objective 
investigations have been used for follow-up in clinical trials by us and others, and the 
outcomes of these tests have always been consistent with clinical outcomes reported 
elsewhere
4,5,6,11
.  
 
Another risk of bias is “selection bias”, which might generate differences between 
participants and non-participants in clinical trials. Patients managed outside clinical trials 
undergo treatment according to their preferences or their surgeon’s preferences, whereas 
within the context of a trial some treatment choices are determined by randomisation. We 
tried to minimise the likelihood of this problem by undertaking the subgroup analysis which 
only included patients undergoing a laparoscopic Nissen fundoplication, and for this analysis 
the 2 groups appeared well matched. Other forms of bias include “detection bias”, which we 
minimised in this study by using the same follow up questionnaire, applied in the same way 
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by the same people, as well as “exclusion bias”, or different rates of follow up. Again, our 
methodology and high rates of follow-up appear to have minimised this problem. 
 
In conclusion, we have demonstrated no disadvantages for entering a randomised clinical trial 
in the context of anti reflux surgery, and this outcome is consistent with findings from the 
domain of oncology. Patients being considered for entry into trials can be reassured that they 
will not be disadvantaged by entering a trial, and by allowing procedure variations to be 
determined by randomisation. Confirmation of these findings in other surgical contexts might 
allow these conclusions to be generalised more widely. 
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TABLES 
 
Table 1 Preoperative demographic data and fundoplication type for all patients in 
Trial vs. Non-trial groups 
 
 Trial group 
(n=417) 
Non-trial group 
(n=981) 
P value 
Male / Female 246 (59.0%) / 171 
(41.0%) 
506 (51.6%) / 475 
(48.4%) 
P=0.012 
BMI 28.7 + 5.7 29.0 + 5.4 P=0.465 
Age at surgery (yrs) 46.7 + 12.6 
(range 18-74) 
49.2 + 13.0  
(range 18-76) 
P=0.0007 
Barrett´s oesophagus 
present 
63 (15.2%) 136 (13.9%) P=0.601 
Fundoplication type    
Nissen 360° 291 (69.8%) 550 (56.1%) P=0.0001 
Anterior 180° partial 64 (15.3%) 270 (27.5%)  
Anterior 90° partial 53 (12.7%) 135 (13.8%)  
Posterior partial 9 (2.2%) 26 (2.7%)  
Data is mean + standard deviation, or number of patients (%). 
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Table 2 Follow-up symptom scores for all patients in Trial vs. Non-trial groups 
 
 Trial group Non-trial group P value 
1 year follow-up    
Dysphagia for liquids 1.1 + 2.0 1.1 + 2.0 p=0.551 
Dysphagia for solids 2.1 + 2.7 2.2 + 2.5 p=0.214 
Heartburn score 0.8 + 1.9 1.4 + 2.2 p<0.0001 
Satisfaction score 8.4 + 2.4 8.3 + 2.4 p=0.244 
5 years follow-up    
Dysphagia for liquids 1.3 + 2.2 1.0 + 1.9 p=0.021 
Dysphagia for solids 2.4 + 2.7 2.1 + 2.6 p=0.127 
Heartburn score 1.7 + 2.6 1.8 + 2.6 p=0.236 
Satisfaction score 8.0 + 2.8 8.0 + 2.7 p=0.556 
All data is mean + standard deviation 
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Table 3 – Preoperative demographic data for Trial vs. Non-trial groups for patients 
aged less than 75 who underwent a Nissen fundoplication  
 
 Trial group 
(n=291) 
Non-trial group 
(n=550) 
P value 
Male / Female 168 (57.7%) / 123 
(42.3%) 
316 (57.5%) / 234 
(42.5%) 
P=0.942 
BMI 28.7 + 5.9 (n=195) 29.5 + 5.6 (n=147)  P=0.250 
Age at surgery (yrs) 46.3 + 11.9 45.6 + 13.0 P=0.372 
Barrett´s 
oesophagus present 
44 (15.1%) 84 (15.3%) p=1.000 
Data is mean + standard deviation, or number of patients (%). 
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Table 4 Follow-up symptom scores for Trial vs. Non-trial groups for patients aged 
less than 75 who underwent a Nissen fundoplication  
 
 Trial group Non-trial group P value 
1 year follow-up    
Dysphagia for liquids 1.2 + 2.1 1.3 + 2.1 P=0.623 
Dysphagia for solids 2.3 + 2.8 2.5 + 2.6 P=0.303 
Heartburn score 0.8 + 1.9 0.01 + 1.9 P=0.238 
Satisfaction score 8.3 + 2.5 8.5 + 2.1 P=0.490 
5 years follow-up    
Dysphagia for liquids 1.4 + 2.3 1.0 + 1.8 P=0.013 
Dysphagia for solids 2.6 + 2.8 2.2 + 2.5 P=0.063 
Heartburn score 1.6 + 2.6 1.2+/-2.0 P<0.0001 
Satisfaction score 7.9 + 2.9 8.2 + 2.5 P=0.148 
All data is mean + standard deviation 
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FIGURE LEGENDS 
 
Figure 1 Flow chart of follow-up for all patients in Trial vs. Non-trial groups. 
 
Figure 2 Flow chart of follow-up for Trial vs. Non-trial groups for patients aged less than 
75 who underwent a Nissen fundoplication. 
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FIGURE 1 
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FIGURE 2 
 
 
 
 
